



For release at 9:00 AM ET on Wednesday, October 4, 2006.

Contact:

Christopher Thurman, +1 404 601-1430, ext. 1419

RFS Pharma, LLC Announces ACLIRES International Ltd. to Conduct Phase 2 HIV Study on Amdoxovir[®]

Tucker, GA, October 4, 2006 — RFS Pharma, LLC, Tucker, Georgia, USA has selected ACLIRES International Ltd., Bermuda, a contract research organization (CRO), to conduct a Phase 2a study with its Buenos Aires affiliate, ACLIRES-Argentina SRL. "We are very pleased to be working with ACLIRES' experienced clinical research team," said Dr. Nancy Kivel, Chief Medical Officer of RFS Pharma. "The data generated from this intensive pharmacokinetic study will be critical for positioning our lead clinical product, DAPD, in pivotal Phase 3 studies."

The study tests the safety, tolerance, pharmacokinetics and antiretroviral activity of RFS Pharma's lead product candidate, amdoxovir[®] (DAPD, AMDX) alone and in combination with retrovir[®] (zidovudine, AZT, ZDV), in untreated HIV-1-infected individuals. It will build on the pillars that have already been established for this drug product candidate in the treatment of HIV-1 infections (Thompson MA et al, AIDS, 19:1607-1615, 2005; Gripshover BM et al, Antiviral Therapy, 11: 619-23, 2006; Margolis D et al, Abstract 13th Conference on Retroviruses and Opportunistic Infections (CROI) 2006, Denver, CO). "We are very happy that RFS Pharma has chosen ACLIRES for this study, and we look forward to initiating this innovative combined modality which could delay or prevent the development of drug resistant HIV," said Dr. Robert Murphy, ACLIRES' Chief Executive Officer.

About amdoxovir[®]

DAPD was in-licensed from Emory University and the University of Georgia Research Foundation (UGARF), where Dr. Raymond F. Schinazi and Dr. Chung K. Chu invented it. DAPD is a nucleoside analog prodrug that is deaminated by adenosine deaminase to its 2'-deoxyguanosine analog, DXG. The triphosphate form of DXG is a potent and selective inhibitor of HIV-1, including drug resistant viruses harboring clinically relevant mutations. It is also active against HIV-2 and hepatitis B virus (HBV). Over 180 subjects have safely received DAPD in six Phase 1 and 2 studies under a US investigational drug application (IND). DAPD has an excellent toxicity profile in subjects receiving treatment for up to 96 weeks and is very effective at decreasing viral load in HIV-1 infected individuals, including those with extensive nucleoside reverse transcriptase inhibitor (NRTI)

mutations. Resistance develops slowly in MT-2 cells and is associated with mutations at K65R or L74V.

About RFS Pharma, LLC

RFS Pharma, LLC, was founded in September 2004 and is located in a 26,500 sq. ft. state-of-the-art research facility in Tucker, Georgia. RFS Pharma is a privately owned biotech company committed to the discovery and development of antiviral agents and other human therapeutics. The company capitalizes on its expertise in nucleoside chemistry to develop drugs to combat infections caused by drug-resistant HIV and hepatitis viruses, as well as to develop drugs to treat inflammation and cancer. For further information about RFS Pharma, please refer to <http://www.rfspharma.com>.

About ACLIRES International Ltd.

ACLIRES International Ltd., founded in 2005, is a specialist provider of clinical Phase 1 and 2 services in South America and Asia. The clinical studies are conducted in dedicated units affiliated with ACLIRES and run by the company's highly trained and experienced personnel. Each unit is housed within a major hospital with access to all critical services.

Amdoxovir[®] and retrovir[®] (AZT) are registered trademarks of RFS Pharma, LLC and GlaxoSmithKline, respectively.

Forward-looking Statements

"Safe Harbor" Statement: Any statements in this press release that relate to the Companies' expectations are forward-looking statements, within the meaning of the US Private Securities Litigation Reform Act of 1995. Since this information may involve risks and uncertainties and be subject to change at any time, the Companies' actual results may differ materially from expected results. The Companies disclaim any obligation to update the statements contained in this press release.

SOURCE: RFS Pharma, LLC and ACLIRES International Ltd.

#####